Full Breakdown
FDA Warns Houston Compounding Pharmacy Over Mass Production of GLP-1 Weight-Loss Drugs
By Drooid · · How we work
FDA Warning to Empower Pharmacy
The Food and Drug Administration issued a warning letter to Empower Pharmacy, a Houston-based compounding pharmacy, for producing “inordinate amounts” of GLP-1 weight-loss medications that the agency says exceed the limits for individualized compounding. The letter, dated in September, gave Empower an opportunity to correct the cited violations. The FDA’s inspection in November 2025 concluded that many of Empower’s orders lacked prescriber documentation showing a “significant difference” from the approved products, and that some rationales appeared to be repeated verbatim. The agency highlighted three primary concerns: missing prescriber justification, duplicated rationales, and the large, undisclosed volume of the drugs produced.
Compounding Pharmacy Regulations and the GLP-1 Surge
Compounding pharmacies traditionally create custom formulations for single patients, such as liquid versions of pills. Federal law permits larger-scale compounding only when a drug shortage is officially declared. In 2022, the FDA announced shortages of Novo Nordisk’s semaglutide (Wegovy, Ozempic) and Eli Lilly’s tirzepide (Zepbound, Mounjaro), prompting many compounders to produce cheaper alternatives. The agency declared the shortage ended in 2025, after which federally licensed compounding facilities largely ceased mass production of these GLP-1 agents. Smaller, state-licensed pharmacies, however, have continued to produce versions by invoking a policy that allows dosage tweaks or vitamin additions when a prescriber asserts a “significant difference” for an individual patient.
Official Positions and Ongoing Litigation
Empower Pharmacy responded that it has already remedied many of the issues identified in the warning and will continue cooperating with the FDA to ensure patient access to quality compounded products. Eli Lilly has filed a lawsuit alleging that Empower’s “personalized” products are deceptive mass-manufactured knockoffs of its FDA-approved medicines. Novo Nordisk has also publicly objected to the practice. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said the FDA’s concern centers not only on volume but on the lack of documentation proving patient-specific need. Darshan Kulkarni, founding partner of the Kulkarni Law Firm and a pharmacy-law expert, described the warning as a “line in the sand” that narrows the pathway for compounded GLP-1 drugs, though he expects pharmacies will adjust their labeling rather than halt production immediately.
Outlook for Compounded GLP-1 Drugs
Analysts suggest the FDA’s action may prompt compounding pharmacies to tighten documentation and limit bulk production, potentially reducing the availability of lower-cost GLP-1 alternatives. The litigation between Eli Lilly and Empower remains unresolved, leaving the future regulatory landscape for compounded weight-loss medications uncertain.